---
document_datetime: 2025-11-23 08:02:32
document_pages: 1
document_pathfilename: www.ema.europa.eu/en/medicines/human/EPAR/biresp-spiromax.html
document_name: biresp-spiromax.html
version: success
processing_time: 0.1303908
conversion_datetime: 2025-12-25 09:09:11.246818
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.66.0
  docling-core: 2.57.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
# BiResp Spiromax

[RSS](/en/individual-human-medicine.xml/66761)

##### Authorised

This medicine is authorised for use in the European Union

budesonide / formoterol

Medicine

Human

Authorised

Page contents

## Page contents

- [Overview](#overview)
- [Product information](#product-info)
- [Product details](#product-details)
- [Authorisation details](#authorisation-details)
- [Assessment history](#assessment-history)
- [News on BiResp Spiromax](#news-on)
- [Topics](#topics)

- Application under evaluation
- CHMP opinion
- European Commission decision

## Overview

BiResp Spiromax is a medicine that contains the active substances budesonide and formoterol. It is used to treat asthma in adults and adolescents aged 12 years and above for whom a combination product is considered appropriate. It can be used in patients whose disease is not adequately controlled by treatment with other asthma medicines called corticosteroids and 'short-acting beta-2 agonists' taken by inhalation, or in patients whose disease is adequately controlled by treatment with corticosteroids and 'long-acting beta-2 agonists' (such as budesonide and formoterol) taken by inhalation.

BiResp Spiromax is also used to relieve the symptoms of severe chronic obstructive pulmonary disease (COPD) in adults who have had exacerbations (flare-ups) of the disease in the past despite regular treatment. COPD is a long-term disease in which the airways and air sacs inside the lungs become damaged or blocked, leading to difficulty in breathing.

BiResp Spiromax is a 'hybrid medicine'. This means that it is similar to a 'reference medicine' containing the same active substances, but BiResp Spiromax is given using a different inhaler. The reference medicine for BiResp Spiromax is Symbicort Turbohaler.

Expand section

Collapse section

## How is BiResp Spiromax used?

The medicine can only be obtained with a prescription. It is available as an inhalation powder in a portable inhaler device, and each inhalation provides a fixed dose of the medicine. BiResp Spiromax 160/4.5 micrograms (160 micrograms of budesonide and 4.5 micrograms of formoterol) can be used for the regular treatment of asthma and when needed as a reliever. It can also be used for the treatment of COPD symptoms in adult patients. The higher strength, BiResp Spiromax 320/9 microgram (320 micrograms of budesonide and 9 micrograms of formoterol), can only be used for the regular treatment of asthma and for the treatment of COPD symptoms.

For the regular treatment of asthma, the recommended dose is 1 to 4 inhalations twice a day, depending on the strength being used, age, and the severity of the asthma. As asthma reliever therapy, patients can take 1 or 2 additional inhalations of BiResp Spiromax 160/4.5 microgram only to relieve their symptoms. If patients need to take more than 8 inhalations per day, it is recommended they speak to their doctor to have their asthma therapy reconsidered.

For the treatment of COPD, the recommended dose is 1 or 2 inhalations twice a day, depending on the strength being used.

For further information, see the package leaflet or contact your doctor or pharmacist..

## How does BiResp Spiromax work?

The two active substances in BiResp Spiromax are well known and are present in several medicines used to treat asthma and COPD, either alone or in combination with other medicines.

Budesonide belongs to a group of anti-inflammatory medicines known as corticosteroids. It works in a similar way to naturally occurring corticosteroid hormones, reducing the activity of the immune system by attaching to receptors in various types of immune cell. This leads to a reduction in the release of substances that are involved in the inflammation process, such as histamine, thereby helping to keep the airways clear and allowing the patient to breathe more easily.

Formoterol is a long-acting beta-2 agonist. It works by attaching to receptors known as beta-2 receptors found in the muscles of the airways. When it attaches to these receptors, it causes the muscles to relax, which keeps the airways open and helps with the patient's breathing.

## How has BiResp Spiromax been studied?

Studies on the benefits and risks of the active substances in the authorised uses have already been carried out with the reference medicine, Symbicort Turbohaler, and do not need to be repeated for BiResp Spiromax.

As for every medicine, the company provided studies on the quality of BiResp Spiromax. The company also carried out studies that showed that it is 'bioequivalent' to the reference medicine. Studies in patients have been limited to tests to determine that BiResp Spiromax is bioequivalent to the reference medicine, Symbicort Turbohaler. Two medicines are bioequivalent when they produce the same levels of the active substance in the body.

## What are the benefits and risks of BiResp Spiromax?

Because BiResp Spiromax is a hybrid medicine and is bioequivalent to the reference medicine, its benefits and risks are taken as being the same as the reference medicine's.

## Why is BiResp Spiromax approved?

The European Medicines Agency concluded that, in accordance with EU requirements, BiResp Spiromax 160/4.5 micrograms and 320/9 micrograms have been shown to have comparable quality and to be bioequivalent to the corresponding strengths of Symbicort Turbohaler. Therefore, the Agency's view was that, as for Symbicort Turbohaler, the benefit outweighs the identified risks and it can be authorised for use in the EU.

## What measures are being taken to ensure the safe and effective use of BiResp Spiromax?

Recommendations and precautions to be followed by healthcare professionals and patients for the safe and effective use of BiResp Spiromax have been included in the summary of product characteristics and the package leaflet.

As for all medicines, data on the use of BiResp Spiromax are continuously monitored. Suspected side effects reported with the medicine are carefully evaluated and any necessary action taken to protect patients.

## Other information about BiResp Spiromax

BiResp Spiromax received a marketing authorisation valid throughout the EU on 28 April 2014.

BiResp Spiromax : EPAR - Summary for the public

Reference Number: EMA/265709/2021

English (EN) (149.11 KB - PDF)

**First published:** 19/05/2014

**Last updated:** 09/06/2021

[View](/en/documents/overview/biresp-spiromax-epar-summary-public_en.pdf)

[Other languages (22)](#file-language-dropdown-591)

български (BG) (175.86 KB - PDF)

**First published:**

19/05/2014

**Last updated:**

09/06/2021

[View](/bg/documents/overview/biresp-spiromax-epar-summary-public_bg.pdf)

español (ES) (150.39 KB - PDF)

**First published:**

19/05/2014

**Last updated:**

09/06/2021

[View](/es/documents/overview/biresp-spiromax-epar-summary-public_es.pdf)

čeština (CS) (174.22 KB - PDF)

**First published:**

19/05/2014

**Last updated:**

09/06/2021

[View](/cs/documents/overview/biresp-spiromax-epar-summary-public_cs.pdf)

dansk (DA) (149.33 KB - PDF)

**First published:**

19/05/2014

**Last updated:**

09/06/2021

[View](/da/documents/overview/biresp-spiromax-epar-summary-public_da.pdf)

Deutsch (DE) (152.28 KB - PDF)

**First published:**

19/05/2014

**Last updated:**

09/06/2021

[View](/de/documents/overview/biresp-spiromax-epar-summary-public_de.pdf)

eesti keel (ET) (149.28 KB - PDF)

**First published:**

19/05/2014

**Last updated:**

09/06/2021

[View](/et/documents/overview/biresp-spiromax-epar-summary-public_et.pdf)

ελληνικά (EL) (176.9 KB - PDF)

**First published:**

19/05/2014

**Last updated:**

09/06/2021

[View](/el/documents/overview/biresp-spiromax-epar-summary-public_el.pdf)

français (FR) (151.18 KB - PDF)

**First published:**

19/05/2014

**Last updated:**

09/06/2021

[View](/fr/documents/overview/biresp-spiromax-epar-summary-public_fr.pdf)

hrvatski (HR) (170.11 KB - PDF)

**First published:**

19/05/2014

**Last updated:**

09/06/2021

[View](/hr/documents/overview/biresp-spiromax-epar-summary-public_hr.pdf)

italiano (IT) (161.02 KB - PDF)

**First published:**

19/05/2014

**Last updated:**

09/06/2021

[View](/it/documents/overview/biresp-spiromax-epar-summary-public_it.pdf)

latviešu valoda (LV) (181.08 KB - PDF)

**First published:**

19/05/2014

**Last updated:**

09/06/2021

[View](/lv/documents/overview/biresp-spiromax-epar-summary-public_lv.pdf)

lietuvių kalba (LT) (174.63 KB - PDF)

**First published:**

19/05/2014

**Last updated:**

09/06/2021

[View](/lt/documents/overview/biresp-spiromax-epar-summary-public_lt.pdf)

magyar (HU) (174.83 KB - PDF)

**First published:**

19/05/2014

**Last updated:**

09/06/2021

[View](/hu/documents/overview/biresp-spiromax-epar-summary-public_hu.pdf)

Malti (MT) (174.44 KB - PDF)

**First published:**

19/05/2014

**Last updated:**

09/06/2021

[View](/mt/documents/overview/biresp-spiromax-epar-summary-public_mt.pdf)

Nederlands (NL) (149.71 KB - PDF)

**First published:**

19/05/2014

**Last updated:**

09/06/2021

[View](/nl/documents/overview/biresp-spiromax-epar-summary-public_nl.pdf)

polski (PL) (175.17 KB - PDF)

**First published:**

19/05/2014

**Last updated:**

09/06/2021

[View](/pl/documents/overview/biresp-spiromax-epar-summary-public_pl.pdf)

português (PT) (150.79 KB - PDF)

**First published:**

19/05/2014

**Last updated:**

09/06/2021

[View](/pt/documents/overview/biresp-spiromax-epar-summary-public_pt.pdf)

română (RO) (170.43 KB - PDF)

**First published:**

19/05/2014

**Last updated:**

09/06/2021

[View](/ro/documents/overview/biresp-spiromax-epar-summary-public_ro.pdf)

slovenčina (SK) (172.43 KB - PDF)

**First published:**

19/05/2014

**Last updated:**

09/06/2021

[View](/sk/documents/overview/biresp-spiromax-epar-summary-public_sk.pdf)

slovenščina (SL) (169.2 KB - PDF)

**First published:**

19/05/2014

**Last updated:**

09/06/2021

[View](/sl/documents/overview/biresp-spiromax-epar-summary-public_sl.pdf)

Suomi (FI) (147.79 KB - PDF)

**First published:**

19/05/2014

**Last updated:**

09/06/2021

[View](/fi/documents/overview/biresp-spiromax-epar-summary-public_fi.pdf)

svenska (SV) (148.48 KB - PDF)

**First published:**

19/05/2014

**Last updated:**

09/06/2021

[View](/sv/documents/overview/biresp-spiromax-epar-summary-public_sv.pdf)

BiResp Spiromax : EPAR - Risk-management-plan summary

English (EN) (528.99 KB - PDF)

**First published:** 19/05/2014

**Last updated:** 09/06/2021

[View](/en/documents/rmp-summary/biresp-spiromax-epar-risk-management-plan-summary_en.pdf)

## Product information

BiResp Spiromax : EPAR - Product Information

English (EN) (810.57 KB - PDF)

**First published:** 19/05/2014

**Last updated:** 24/07/2024

[View](/en/documents/product-information/biresp-spiromax-epar-product-information_en.pdf)

[Other languages (24)](#file-language-dropdown-837)

български (BG) (902.5 KB - PDF)

**First published:**

19/05/2014

**Last updated:**

24/07/2024

[View](/bg/documents/product-information/biresp-spiromax-epar-product-information_bg.pdf)

español (ES) (762.81 KB - PDF)

**First published:**

19/05/2014

**Last updated:**

24/07/2024

[View](/es/documents/product-information/biresp-spiromax-epar-product-information_es.pdf)

čeština (CS) (903.36 KB - PDF)

**First published:**

19/05/2014

**Last updated:**

24/07/2024

[View](/cs/documents/product-information/biresp-spiromax-epar-product-information_cs.pdf)

dansk (DA) (758.51 KB - PDF)

**First published:**

19/05/2014

**Last updated:**

24/07/2024

[View](/da/documents/product-information/biresp-spiromax-epar-product-information_da.pdf)

Deutsch (DE) (823.26 KB - PDF)

**First published:**

19/05/2014

**Last updated:**

24/07/2024

[View](/de/documents/product-information/biresp-spiromax-epar-product-information_de.pdf)

eesti keel (ET) (802.08 KB - PDF)

**First published:**

19/05/2014

**Last updated:**

24/07/2024

[View](/et/documents/product-information/biresp-spiromax-epar-product-information_et.pdf)

ελληνικά (EL) (976.22 KB - PDF)

**First published:**

19/05/2014

**Last updated:**

24/07/2024

[View](/el/documents/product-information/biresp-spiromax-epar-product-information_el.pdf)

français (FR) (808.75 KB - PDF)

**First published:**

19/05/2014

**Last updated:**

24/07/2024

[View](/fr/documents/product-information/biresp-spiromax-epar-product-information_fr.pdf)

hrvatski (HR) (854.8 KB - PDF)

**First published:**

19/05/2014

**Last updated:**

24/07/2024

[View](/hr/documents/product-information/biresp-spiromax-epar-product-information_hr.pdf)

íslenska (IS) (770.59 KB - PDF)

**First published:**

19/05/2014

**Last updated:**

24/07/2024

[View](/is/documents/product-information/biresp-spiromax-epar-product-information_is.pdf)

italiano (IT) (770.17 KB - PDF)

**First published:**

19/05/2014

**Last updated:**

24/07/2024

[View](/it/documents/product-information/biresp-spiromax-epar-product-information_it.pdf)

latviešu valoda (LV) (868.94 KB - PDF)

**First published:**

19/05/2014

**Last updated:**

24/07/2024

[View](/lv/documents/product-information/biresp-spiromax-epar-product-information_lv.pdf)

lietuvių kalba (LT) (884.78 KB - PDF)

**First published:**

19/05/2014

**Last updated:**

24/07/2024

[View](/lt/documents/product-information/biresp-spiromax-epar-product-information_lt.pdf)

magyar (HU) (877.53 KB - PDF)

**First published:**

19/05/2014

**Last updated:**

24/07/2024

[View](/hu/documents/product-information/biresp-spiromax-epar-product-information_hu.pdf)

Malti (MT) (994.28 KB - PDF)

**First published:**

19/05/2014

**Last updated:**

24/07/2024

[View](/mt/documents/product-information/biresp-spiromax-epar-product-information_mt.pdf)

Nederlands (NL) (774.26 KB - PDF)

**First published:**

19/05/2014

**Last updated:**

24/07/2024

[View](/nl/documents/product-information/biresp-spiromax-epar-product-information_nl.pdf)

norsk (NO) (797.21 KB - PDF)

**First published:**

19/05/2014

**Last updated:**

24/07/2024

[View](/no/documents/product-information/biresp-spiromax-epar-product-information_no.pdf)

polski (PL) (939.99 KB - PDF)

**First published:**

19/05/2014

**Last updated:**

24/07/2024

[View](/pl/documents/product-information/biresp-spiromax-epar-product-information_pl.pdf)

português (PT) (805.84 KB - PDF)

**First published:**

19/05/2014

**Last updated:**

24/07/2024

[View](/pt/documents/product-information/biresp-spiromax-epar-product-information_pt.pdf)

română (RO) (895.53 KB - PDF)

**First published:**

19/05/2014

**Last updated:**

24/07/2024

[View](/ro/documents/product-information/biresp-spiromax-epar-product-information_ro.pdf)

slovenčina (SK) (878.66 KB - PDF)

**First published:**

19/05/2014

**Last updated:**

24/07/2024

[View](/sk/documents/product-information/biresp-spiromax-epar-product-information_sk.pdf)

slovenščina (SL) (855.63 KB - PDF)

**First published:**

19/05/2014

**Last updated:**

24/07/2024

[View](/sl/documents/product-information/biresp-spiromax-epar-product-information_sl.pdf)

Suomi (FI) (783.22 KB - PDF)

**First published:**

19/05/2014

**Last updated:**

24/07/2024

[View](/fi/documents/product-information/biresp-spiromax-epar-product-information_fi.pdf)

svenska (SV) (746.17 KB - PDF)

**First published:**

19/05/2014

**Last updated:**

24/07/2024

[View](/sv/documents/product-information/biresp-spiromax-epar-product-information_sv.pdf)

**Latest procedure affecting product information:** IG1765 18/07/2024

icon globe

<!-- image -->

This medicine's product information is available in all **official EU languages** . Select 'available languages' to access the language you need.

Product information documents contain:

- summary of product characteristics (annex I);
- manufacturing authorisation holder responsible for batch release (annex IIA);
- conditions of the marketing authorisation (annex IIB);
- labelling (annex IIIA);
- package leaflet (annex IIIB).

BiResp Spiromax : EPAR - All Authorised presentations

English (EN) (26.51 KB - PDF)

**First published:** 19/05/2014

**Last updated:** 19/05/2014

[View](/en/documents/all-authorised-presentations/biresp-spiromax-epar-all-authorised-presentations_en.pdf)

[Other languages (24)](#file-language-dropdown-388)

български (BG) (46.28 KB - PDF)

**First published:**

19/05/2014

**Last updated:**

19/05/2014

[View](/bg/documents/all-authorised-presentations/biresp-spiromax-epar-all-authorised-presentations_bg.pdf)

español (ES) (29.65 KB - PDF)

**First published:**

19/05/2014

**Last updated:**

19/05/2014

[View](/es/documents/all-authorised-presentations/biresp-spiromax-epar-all-authorised-presentations_es.pdf)

čeština (CS) (33.76 KB - PDF)

**First published:**

19/05/2014

**Last updated:**

19/05/2014

[View](/cs/documents/all-authorised-presentations/biresp-spiromax-epar-all-authorised-presentations_cs.pdf)

dansk (DA) (27.97 KB - PDF)

**First published:**

19/05/2014

**Last updated:**

19/05/2014

[View](/da/documents/all-authorised-presentations/biresp-spiromax-epar-all-authorised-presentations_da.pdf)

Deutsch (DE) (26.84 KB - PDF)

**First published:**

19/05/2014

**Last updated:**

19/05/2014

[View](/de/documents/all-authorised-presentations/biresp-spiromax-epar-all-authorised-presentations_de.pdf)

eesti keel (ET) (26.72 KB - PDF)

**First published:**

19/05/2014

**Last updated:**

19/05/2014

[View](/et/documents/all-authorised-presentations/biresp-spiromax-epar-all-authorised-presentations_et.pdf)

ελληνικά (EL) (44.7 KB - PDF)

**First published:**

19/05/2014

**Last updated:**

19/05/2014

[View](/el/documents/all-authorised-presentations/biresp-spiromax-epar-all-authorised-presentations_el.pdf)

français (FR) (27.04 KB - PDF)

**First published:**

19/05/2014

**Last updated:**

19/05/2014

[View](/fr/documents/all-authorised-presentations/biresp-spiromax-epar-all-authorised-presentations_fr.pdf)

hrvatski (HR) (33.76 KB - PDF)

**First published:**

19/05/2014

**Last updated:**

19/05/2014

[View](/hr/documents/all-authorised-presentations/biresp-spiromax-epar-all-authorised-presentations_hr.pdf)

íslenska (IS) (26.82 KB - PDF)

**First published:**

19/05/2014

**Last updated:**

19/05/2014

[View](/is/documents/all-authorised-presentations/biresp-spiromax-epar-all-authorised-presentations_is.pdf)

italiano (IT) (23.82 KB - PDF)

**First published:**

19/05/2014

**Last updated:**

19/05/2014

[View](/it/documents/all-authorised-presentations/biresp-spiromax-epar-all-authorised-presentations_it.pdf)

latviešu valoda (LV) (43.57 KB - PDF)

**First published:**

19/05/2014

**Last updated:**

19/05/2014

[View](/lv/documents/all-authorised-presentations/biresp-spiromax-epar-all-authorised-presentations_lv.pdf)

lietuvių kalba (LT) (42.15 KB - PDF)

**First published:**

19/05/2014

**Last updated:**

19/05/2014

[View](/lt/documents/all-authorised-presentations/biresp-spiromax-epar-all-authorised-presentations_lt.pdf)

magyar (HU) (27.41 KB - PDF)

**First published:**

19/05/2014

**Last updated:**

19/05/2014

[View](/hu/documents/all-authorised-presentations/biresp-spiromax-epar-all-authorised-presentations_hu.pdf)

Malti (MT) (44.82 KB - PDF)

**First published:**

19/05/2014

**Last updated:**

19/05/2014

[View](/mt/documents/all-authorised-presentations/biresp-spiromax-epar-all-authorised-presentations_mt.pdf)

Nederlands (NL) (26.67 KB - PDF)

**First published:**

19/05/2014

**Last updated:**

19/05/2014

[View](/nl/documents/all-authorised-presentations/biresp-spiromax-epar-all-authorised-presentations_nl.pdf)

norsk (NO) (26.53 KB - PDF)

**First published:**

19/05/2014

**Last updated:**

19/05/2014

[View](/no/documents/all-authorised-presentations/biresp-spiromax-epar-all-authorised-presentations_no.pdf)

polski (PL) (34.37 KB - PDF)

**First published:**

19/05/2014

**Last updated:**

19/05/2014

[View](/pl/documents/all-authorised-presentations/biresp-spiromax-epar-all-authorised-presentations_pl.pdf)

português (PT) (26.75 KB - PDF)

**First published:**

19/05/2014

**Last updated:**

19/05/2014

[View](/pt/documents/all-authorised-presentations/biresp-spiromax-epar-all-authorised-presentations_pt.pdf)

română (RO) (34.56 KB - PDF)

**First published:**

19/05/2014

**Last updated:**

19/05/2014

[View](/ro/documents/all-authorised-presentations/biresp-spiromax-epar-all-authorised-presentations_ro.pdf)

slovenčina (SK) (42.86 KB - PDF)

**First published:**

19/05/2014

**Last updated:**

19/05/2014

[View](/sk/documents/all-authorised-presentations/biresp-spiromax-epar-all-authorised-presentations_sk.pdf)

slovenščina (SL) (26.63 KB - PDF)

**First published:**

19/05/2014

**Last updated:**

19/05/2014

[View](/sl/documents/all-authorised-presentations/biresp-spiromax-epar-all-authorised-presentations_sl.pdf)

Suomi (FI) (25.82 KB - PDF)

**First published:**

19/05/2014

**Last updated:**

19/05/2014

[View](/fi/documents/all-authorised-presentations/biresp-spiromax-epar-all-authorised-presentations_fi.pdf)

svenska (SV) (26.76 KB - PDF)

**First published:**

19/05/2014

**Last updated:**

19/05/2014

[View](/sv/documents/all-authorised-presentations/biresp-spiromax-epar-all-authorised-presentations_sv.pdf)

## Product details

Name of medicine BiResp Spiromax Active substance

- Budesonide
- formoterol fumarate dihydrate

International non-proprietary name (INN) or common name

- budesonide
- formoterol

Therapeutic area (MeSH)

- Pulmonary Disease, Chronic Obstructive
- Asthma

Anatomical therapeutic chemical (ATC) code R03AK07

### Pharmacotherapeutic group

Drugs for obstructive airway diseases

### Therapeutic indication

**Asthma**

BiResp Spiromax is indicated in adults and adolescents (12 years and older) for the regular treatment of asthma, where use of a combination (inhaled corticosteroid and long-acting ?? adrenoceptor agonist) is appropriate:

- in patients not adequately controlled with inhaled corticosteroids and \"as needed\" inhaled short-acting ?? adrenoceptor agonists.

or

- in patients already adequately controlled on both inhaled corticosteroids and long-acting ?? adrenoceptor agonists.

**COPD**

## Authorisation details

EMA product number EMEA/H/C/003890 Marketing authorisation holder

Teva Pharma B.V.

Computerweg 10 3542 DR Utrecht The Netherlands

Marketing authorisation issued 28/04/2014 Revision 13

## Assessment history

Expand section

Collapse section

## Changes since initial authorisation of medicine

BiResp Spiromax : EPAR - Procedural steps taken and scientific information after authorisation

English (EN) (189.24 KB - PDF)

**First published:** 30/10/2015

**Last updated:** 24/07/2024

[View](/en/documents/procedural-steps-after/biresp-spiromax-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf)

BiResp Spiromax-H-C-3890-II-0033 : EPAR - Assessment Report - Variation

Adopted

Reference Number: EMA/CHMP/310289/2021

English (EN) (939.49 KB - PDF)

**First published:** 09/06/2021

[View](/en/documents/variation-report/biresp-spiromax-h-c-3890-ii-0033-epar-assessment-report-variation_en.pdf)

CHMP post-authorisation summary of positive opinion for BiResp Spiromax (II-33-G)

Adopted

Reference Number: EMA/CHMP/218046/2021

English (EN) (137.9 KB - PDF)

**First published:** 23/04/2021

[View](/en/documents/smop/chmp-post-authorisation-summary-positive-opinion-biresp-spiromax-ii-33-g_en.pdf)

BiResp Spiromax-H-C-PSUSA-00010585-201908 : EPAR - Scientific conclusions and grounds for the variation to the terms of the marketing authorisation

Adopted

Reference Number: EMA/271549/2020

English (EN) (143.41 KB - PDF)

**First published:** 31/07/2020

[View](/en/documents/scientific-conclusion/biresp-spiromax-h-c-psusa-00010585-201908-epar-scientific-conclusions-and-grounds-variation-terms-marketing-authorisation_en.pdf)

BiResp Spiromax : EPAR - Scientific Conclusion

English (EN) (39.48 KB - PDF)

**First published:** 15/07/2016

**Last updated:** 15/07/2016

[View](/en/documents/scientific-conclusion/biresp-spiromax-epar-scientific-conclusion_en.pdf)

[Other languages (22)](#file-language-dropdown-909)

български (BG) (71.2 KB - PDF)

**First published:**

15/07/2016

**Last updated:**

15/07/2016

[View](/bg/documents/scientific-conclusion/biresp-spiromax-epar-scientific-conclusion_bg.pdf)

español (ES) (39.85 KB - PDF)

**First published:**

15/07/2016

**Last updated:**

15/07/2016

[View](/es/documents/scientific-conclusion/biresp-spiromax-epar-scientific-conclusion_es.pdf)

čeština (CS) (71.36 KB - PDF)

**First published:**

15/07/2016

**Last updated:**

15/07/2016

[View](/cs/documents/scientific-conclusion/biresp-spiromax-epar-scientific-conclusion_cs.pdf)

dansk (DA) (38.68 KB - PDF)

**First published:**

15/07/2016

**Last updated:**

15/07/2016

[View](/da/documents/scientific-conclusion/biresp-spiromax-epar-scientific-conclusion_da.pdf)

Deutsch (DE) (41.37 KB - PDF)

**First published:**

15/07/2016

**Last updated:**

15/07/2016

[View](/de/documents/scientific-conclusion/biresp-spiromax-epar-scientific-conclusion_de.pdf)

eesti keel (ET) (46.81 KB - PDF)

**First published:**

15/07/2016

**Last updated:**

15/07/2016

[View](/et/documents/scientific-conclusion/biresp-spiromax-epar-scientific-conclusion_et.pdf)

ελληνικά (EL) (74.71 KB - PDF)

**First published:**

15/07/2016

**Last updated:**

15/07/2016

[View](/el/documents/scientific-conclusion/biresp-spiromax-epar-scientific-conclusion_el.pdf)

français (FR) (39.98 KB - PDF)

**First published:**

15/07/2016

**Last updated:**

15/07/2016

[View](/fr/documents/scientific-conclusion/biresp-spiromax-epar-scientific-conclusion_fr.pdf)

hrvatski (HR) (66.46 KB - PDF)

**First published:**

15/07/2016

**Last updated:**

15/07/2016

[View](/hr/documents/scientific-conclusion/biresp-spiromax-epar-scientific-conclusion_hr.pdf)

italiano (IT) (38.8 KB - PDF)

**First published:**

15/07/2016

**Last updated:**

15/07/2016

[View](/it/documents/scientific-conclusion/biresp-spiromax-epar-scientific-conclusion_it.pdf)

latviešu valoda (LV) (66.17 KB - PDF)

**First published:**

15/07/2016

**Last updated:**

15/07/2016

[View](/lv/documents/scientific-conclusion/biresp-spiromax-epar-scientific-conclusion_lv.pdf)

lietuvių kalba (LT) (68.75 KB - PDF)

**First published:**

15/07/2016

**Last updated:**

15/07/2016

[View](/lt/documents/scientific-conclusion/biresp-spiromax-epar-scientific-conclusion_lt.pdf)

magyar (HU) (57.06 KB - PDF)

**First published:**

15/07/2016

**Last updated:**

15/07/2016

[View](/hu/documents/scientific-conclusion/biresp-spiromax-epar-scientific-conclusion_hu.pdf)

Malti (MT) (71.25 KB - PDF)

**First published:**

15/07/2016

**Last updated:**

15/07/2016

[View](/mt/documents/scientific-conclusion/biresp-spiromax-epar-scientific-conclusion_mt.pdf)

Nederlands (NL) (39.18 KB - PDF)

**First published:**

15/07/2016

**Last updated:**

15/07/2016

[View](/nl/documents/scientific-conclusion/biresp-spiromax-epar-scientific-conclusion_nl.pdf)

polski (PL) (53.28 KB - PDF)

**First published:**

15/07/2016

**Last updated:**

15/07/2016

[View](/pl/documents/scientific-conclusion/biresp-spiromax-epar-scientific-conclusion_pl.pdf)

português (PT) (39.31 KB - PDF)

**First published:**

15/07/2016

**Last updated:**

15/07/2016

[View](/pt/documents/scientific-conclusion/biresp-spiromax-epar-scientific-conclusion_pt.pdf)

română (RO) (68.61 KB - PDF)

**First published:**

15/07/2016

**Last updated:**

15/07/2016

[View](/ro/documents/scientific-conclusion/biresp-spiromax-epar-scientific-conclusion_ro.pdf)

slovenčina (SK) (68.56 KB - PDF)

**First published:**

15/07/2016

**Last updated:**

15/07/2016

[View](/sk/documents/scientific-conclusion/biresp-spiromax-epar-scientific-conclusion_sk.pdf)

slovenščina (SL) (65.75 KB - PDF)

**First published:**

15/07/2016

**Last updated:**

15/07/2016

[View](/sl/documents/scientific-conclusion/biresp-spiromax-epar-scientific-conclusion_sl.pdf)

Suomi (FI) (38.28 KB - PDF)

**First published:**

15/07/2016

**Last updated:**

15/07/2016

[View](/fi/documents/scientific-conclusion/biresp-spiromax-epar-scientific-conclusion_fi.pdf)

svenska (SV) (39.25 KB - PDF)

**First published:**

15/07/2016

**Last updated:**

15/07/2016

[View](/sv/documents/scientific-conclusion/biresp-spiromax-epar-scientific-conclusion_sv.pdf)

BiResp Spiromax-H-C-3890-A31-14165: EPAR - Assessment Report - Article 31

Adopted

Reference Number: EMA/330021/2016

English (EN) (228.27 KB - PDF)

**First published:** 15/07/2016

**Last updated:** 15/07/2016

[View](/en/documents/variation-report/biresp-spiromax-h-c-3890-a31-14165-epar-assessment-report-article-31_en.pdf)

## Initial marketing authorisation documents

BiResp Spiromax : EPAR - Public assessment report

Adopted

Reference Number: EMA/CHMP/175684/2014

English (EN) (1.72 MB - PDF)

**First published:** 19/05/2014

**Last updated:** 19/05/2014

[View](/en/documents/assessment-report/biresp-spiromax-epar-public-assessment-report_en.pdf)

CHMP summary of positive opinion for BiResp Spiromax

Adopted

Reference Number: EMA/CHMP/68061/2014

English (EN) (101.05 KB - PDF)

**First published:** 21/02/2014

**Last updated:** 21/02/2014

[View](/en/documents/smop-initial/chmp-summary-positive-opinion-biresp-spiromax_en.pdf)

#### News on BiResp Spiromax

[Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 19-22 April 2021](/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-19-22-april-2021) 23/04/2021

[Meeting highlights from the Pharmacovigilance Risk Assessment Committee (PRAC) 4-7 May 2015](/en/news/meeting-highlights-pharmacovigilance-risk-assessment-committee-prac-4-7-may-2015) 08/05/2015

[Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 17-20 February 2014](/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-17-20-february-2014) 21/02/2014

#### Topics

- [Medicines](https://www.ema.europa.eu/en/search?f%5B0%5D=ema_search_topics%3A61)

**This page was last updated on** 24/07/2024

## Share this page

[Back to top](#main-content)